Table 5.
Listed on COPD register | |||||
Yes (n=78) | No (n=297) | ||||
N* | (%) | N* | (%) | ||
Informed about COPD diagnosis | 69 | 88.5 | 52 | 17.5 | |
Annual review undertaken | 65 | 83.3 | 103 | 34.7 | |
Spirometry undertaken | 68 | 87.2 | 111 | 37.4 | |
Inhaler technique assessed | 37 | 47.4 | 72 | 24.2 | |
Antibiotics prescribed | 14 | 17.9 | 18 | 6.1 | |
Steroids prescribed | 13 | 16.7 | 14 | 4.7 | |
Influenza vaccine offered | 77 | 98.7 | 242 | 81.5 | |
Influenza vaccine received | 67 | 85.9 | 207 | 69.7 | |
Pneumococcal vaccine offered | 44 | 56.4 | 128 | 43.1 | |
Pneumococcal vaccine received | 43 | 55.1 | 121 | 40.7 | |
Pulmonary rehabilitation offered | 4 | 5.1 | 5 | 1.7 | |
Attended pulmonary rehabilitation | 3 | 3.8 | 6 | 2 | |
Smoking cessation advice given | 44 | 56.4 | 103 | 34.7 | |
Smoking cessation support offered† | 34 | 43.6 | 60 | 20.2 | |
Inhalers prescribed | SABA | 45 | 57.7 | 87 | 29.3 |
SAMA | 21 | 26.9 | 18 | 6.1 | |
ICS | 5 | 6.4 | 23 | 7.7 | |
LABA | 0 | 0 | 5 | 1.7 | |
LAMA | 7 | 9 | 1 | 0.3 | |
ICS/LABA | 17 | 21.8 | 40 | 13.5 | |
LABA/LAMA | 2 | 2.6 | 2 | 0.7 | |
Any of the above | 58 | 74.4 | 104 | 35 | |
Care plan provided | 62 | 79.5 | 39 | 13.1 | |
Clinical care score | <5 | 9 | 11.5 | 214 | 72.1 |
5–9 | 56 | 71.8 | 76 | 25.6 | |
≥10 | 13 | 16.7 | 7 | 2.4 | |
Median (IQR) | 8 | (6–9) | 3 | (2–5) |
*Number of participants self-reporting having received the clinical intervention.
†19/25 (76%) smokers listed on the COPD Quality and Outcomes Framework (QOF) register received smoking cessation support and 34/54 (63%) smokers not listedon the COPD QOF register had received this.
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; IQR, Interquartile range; LABA, long acting beta 2 agonist; LAMA, long acting muscarinic antagonist; SABA, short acting beta 2 antagonist; SAMA, short acting muscarinic antagonist.